You have 9 free searches left this month | to do more

venetoclax

Venetoclax is a drug used to treat Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and other conditions. Venetoclax is being actively studied in 234 studies and prior, has been studied in 25.

Top SponsorsTop SitesTop Investigators
AbbVieM D Anderson Cancer CenterMatthew S. Davids, MD
M.D. Anderson Cancer CenterMD Anderson Cancer CenterPaolo Ghia
Hoffmann-La RocheDana Farber Cancer InstituteAndrew Lane
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax
  • Taipei, Taiwan
    National Taiwan University Hospital
2021-10-27
Oct 27, 2021
U
CC-486 and Venetoclax for Acute Myeloid Leukemia
Recruiting
  • AML
  • Aurora, Colorado
  • +1 more
2022-04-04
Apr 4, 2022
N
Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia
Recruiting
  • Chronic Lymphocytic Leukemia
  • Venetoclax
  • Taipei, Taiwan
    National Taiwan University Hospital
2021-10-27
Oct 27, 2021
D
Safe Accelerated Venetoclax Escalation in CLL
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Venetoclax
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-09-08
Sep 8, 2021
N
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
2022-03-29
Mar 29, 2022
D
Ibrutinib + Venetoclax in Untreated WM
Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • MYD88 Gene Mutation
  • Boston, Massachusetts
  • +1 more
2022-04-01
Apr 1, 2022
A
Expanded Access to Venetoclax
Available
  • Chronic Lymphocytic Leukemia (CLL)
  • +6 more
  • Venetoclax
  • (no location specified)
2022-03-28
Mar 28, 2022
M
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
Not yet recruiting
  • CLL
  • (no location specified)
2022-02-08
Feb 8, 2022
U
Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • Aurora, Colorado
    Universtiy of Colorado Hospital
2022-02-15
Feb 15, 2022
C
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
Recruiting
  • AML, Adult
  • Chemotherapy Effect
  • Venetoclax
  • +3 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
2022-02-28
Feb 28, 2022
M
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • Venetoclax
  • +5 more
  • (no location specified)
2022-03-30
Mar 30, 2022
U
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
Recruiting
  • Chronic Lymphocytic Leukemia
  • San Diego, California
    UCSD Koman Family Outpatient Pavilion
2021-11-24
Nov 24, 2021
C
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Duarte, California
    City of Hope Comprehensive Cancer Center
2022-02-08
Feb 8, 2022
L
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
2022-03-04
Mar 4, 2022
P
Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer
Recruiting
  • Breast Neoplasm Female
  • Venetoclax
  • +2 more
  • Melbourne, Victoria, Australia
  • +2 more
2022-03-10
Mar 10, 2022
K
Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma - 2021
Terminated
  • Primary CNS Lymphoma
  • Stuttgart, Baden-Württemberg, Germany
    Klinikum Stuttgart
2022-01-18
Jan 18, 2022
K
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance - 2021
Withdrawn
  • Chronic Lymphocytic Leukemia
  • Loss of Chromosome 17p
  • (no location specified)
2021-10-29
Oct 29, 2021
C
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Suspended
  • Leukemia
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
2021-12-29
Dec 29, 2021
J
Zanubrutinib + Venetoclax in CLL/SLL
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
2022-03-16
Mar 16, 2022
D
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-11-02
Nov 2, 2021
U
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
Not yet recruiting
  • Myeloproliferative Neoplasm
  • BCR-ABL Negative
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
2021-09-29
Sep 29, 2021
M
Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma
Withdrawn
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-23
Feb 23, 2022
D
Copanlisib Plus Venetoclax in R/R DLBCL
Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-09-08
Sep 8, 2021
M
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2022-04-07
Apr 7, 2022
D
Venetoclax Plus Inotuzumab for B-ALL
Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Venetoclax
  • +2 more
  • Boston, Massachusetts
  • +1 more
2021-10-19
Oct 19, 2021